VBI Vaccines announced that the U.S. Food and Drug Administration (FDA) granted Fast Track Designation for VBI-1901, VBI’s cancer vaccine immunotherapeutic candidate for the treatment of recurrent glioblastoma (GBM) patients with first tumor recurrence.
https://www.vbivaccines.com/press-releases/vbi-1901-gbm-fda-fast-track-designation/
